Insider Buying: Perspective Therapeutics, Inc. (NYSE:CATX) CEO Buys 22,026 Shares of Stock

Perspective Therapeutics, Inc. (NYSE:CATX) CEO Johan M. Spoor purchased 22,026 shares of the stock in a transaction on Friday, March 28th. The stock was bought at an average cost of $2.24 per share, for a total transaction of $49,338.24. Following the completion of the acquisition, the chief executive officer now owns 59,383 shares in the company, valued at approximately $133,017.92. This trade represents a 58.96 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

Perspective Therapeutics Stock Down 8.0 %

NYSE CATX traded down $0.17 during trading on Tuesday, hitting $1.96. 891,750 shares of the company’s stock were exchanged, compared to its average volume of 999,366. The stock’s 50 day moving average price is $2.91 and its two-hundred day moving average price is $6.19. Perspective Therapeutics, Inc. has a fifty-two week low of $1.91 and a fifty-two week high of $19.05.

Hedge Funds Weigh In On Perspective Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in CATX. Intech Investment Management LLC bought a new stake in Perspective Therapeutics during the 3rd quarter worth $137,000. Charles Schwab Investment Management Inc. boosted its stake in shares of Perspective Therapeutics by 221.7% during the third quarter. Charles Schwab Investment Management Inc. now owns 433,522 shares of the company’s stock valued at $5,788,000 after purchasing an additional 298,778 shares in the last quarter. The Manufacturers Life Insurance Company increased its stake in shares of Perspective Therapeutics by 8.9% in the third quarter. The Manufacturers Life Insurance Company now owns 20,514 shares of the company’s stock valued at $274,000 after buying an additional 1,672 shares during the period. FMR LLC raised its holdings in Perspective Therapeutics by 3,994.9% in the 3rd quarter. FMR LLC now owns 5,504,822 shares of the company’s stock valued at $73,489,000 after buying an additional 5,370,392 shares during the last quarter. Finally, BNP Paribas Financial Markets boosted its position in Perspective Therapeutics by 1,302.7% during the 3rd quarter. BNP Paribas Financial Markets now owns 47,565 shares of the company’s stock worth $635,000 after buying an additional 44,174 shares during the period. Institutional investors own 54.66% of the company’s stock.

Analyst Ratings Changes

CATX has been the topic of several research reports. Cantor Fitzgerald raised Perspective Therapeutics to a “strong-buy” rating in a research report on Tuesday, March 4th. Brookline Capital Management raised Perspective Therapeutics to a “strong-buy” rating in a report on Monday, March 10th. Wedbush reissued an “outperform” rating and set a $11.00 price target on shares of Perspective Therapeutics in a research report on Wednesday, March 26th. HC Wainwright reiterated a “buy” rating and set a $10.00 target price on shares of Perspective Therapeutics in a research report on Monday. Finally, Lifesci Capital upgraded Perspective Therapeutics to a “strong-buy” rating in a research report on Thursday, March 6th. One equities research analyst has rated the stock with a hold rating, eight have assigned a buy rating and three have assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus target price of $14.44.

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.